focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Jul 2021 10:50

RNS Number : 4912F
Hutchmed (China) Limited
16 July 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

HUTCHMED (China) Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Canada Pension Plan Investment Board

City and country of registered office (if applicable)

Toronto, Canada

4. Full name of shareholder(s) (if different from 3.) v

Name

N/A

City and country of registered office (if applicable)

N/A

5. Date on which the threshold was crossed or reached vi:

30 June 2021

6. Date on which issuer notified (DD/MM/YYYY):

16 July 2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

3.17%

0.00

3.17%

26,883,270

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary Shares

KYG4672N1198

 

26,883,270

0

3.17%

0.00

SUBTOTAL 8. A

26,883,270

3.17%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8. B 1

N/A

N/A

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

N/A

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8.B.2

N/A

N/A

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

N/A

N/A

N/A

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information xvi

N/A

 

Place of completion

Hong Kong

Date of completion

16 July 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEANXKFLDFEEA
Date   Source Headline
31st May 20167:00 amRNSTotal Voting Rights
13th May 20167:00 amRNSEnrollment completion of Phase III fruquintinib
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20161:12 pmRNSResults of Annual General Meeting
13th Apr 20164:23 pmRNSExercise of Overallotment Option
31st Mar 20167:00 amRNSTotal Voting Rights
29th Mar 20168:00 amRNSDirector/PDMR Shareholding
23rd Mar 201610:34 amRNSHolding(s) in Company
22nd Mar 20162:00 pmRNSClosing of U.S. Public Offering of ADSs
21st Mar 20168:54 amRNSDirector/PDMR Shareholding
21st Mar 20167:00 amRNSSulfatinib Phase III registration study
18th Mar 20164:18 pmRNSFinal Prospectus
17th Mar 20167:00 amRNSPricing of U.S. Public Offering of ADSs
15th Mar 20167:00 amRNS2015 Annual Report and Notice of AGM
7th Mar 20167:59 amRNSFifth Filing of Form F-1 Registration Statement
4th Mar 20166:12 pmRNSLaunch of Potential U.S. Public Offering of ADSs
4th Mar 20165:54 pmRNSFifth Filing of Form F-1 Registration Statement
2nd Mar 20167:00 amRNSSulfatinib Phase II initation in thyroid cancer
1st Mar 20164:29 pmRNSFourth Filing of Form F-1 Registration Statement
1st Mar 20167:00 amRNSFinal Results
11th Feb 20165:39 pmRNSPublic Filing of Form F-1 Registration Statement
29th Jan 20168:03 amRNSNotice of Results
15th Jan 20167:02 amRNSChi-Med initiates HMPL-523 Phase I clinical trial
29th Dec 20157:43 amRNSBlocklisting Six Monthly Return
18th Dec 20157:00 amRNSInitiation sulfatinib Phase III registration study
9th Dec 20157:00 amRNSUS$105 m Shanghai land compensation agreement
8th Dec 20157:00 amRNSInitiation of fruquintinib Phase 3 trial in NSCLC
13th Nov 20152:50 pmRNSSecond Public Filing of Registration Statement
10th Nov 20151:13 pmRNSResults of Extraordinary General Meeting
9th Nov 20157:59 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSChi-Med initiates sulfatinib U.S. clinical trials
30th Oct 20157:00 amRNSClinical results presented
30th Oct 20157:00 amRNSTotal Voting Rights
30th Oct 20157:00 amRNSCompletion of Phase I clinical trial of HMPL 523
20th Oct 20152:40 pmRNSDirector's Share Dealing
19th Oct 20157:00 amRNSAwards under Long Term Incentive Plan
16th Oct 201512:17 pmRNSShareholders' Circular and Notice of EGM
16th Oct 201512:15 pmRNSFiling of Registration Statement on Form F1
16th Oct 201512:03 pmRNSChi-Med files Nasdaq Registration Statement
13th Oct 20157:00 amRNSEnrolment complete in Savolitinib Phase II trial
12th Oct 20152:09 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSPresentation at 2015 European Cancer Congress
2nd Sep 201511:57 amRNSTrial of fruquintinib achieves primary endpoint
19th Aug 201512:14 pmRNSTermination of R&D agreement with Janssen
28th Jul 20157:00 amRNSInterim Results
23rd Jul 20151:05 pmRNSNotification of major interest in shares
23rd Jul 20151:01 pmRNSNotification of major interest in shares
23rd Jul 20159:01 amRNSMitsui exchanges shares in Hutchison MediPharma
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.